Aurinia Pharmaceuticals (AUP) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock AUP Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Implied Volatility Surging for Aurinia Pharmaceuticals Stock OptionsJuly 2, 2025 | msn.comRetail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial ResultsJune 30, 2025 | msn.comAurinia outlines $250M–$260M 2025 revenue target as LUPKYNIS sales climb 25% and operational efficiency improvesMay 12, 2025 | msn.comAurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in MarchMarch 25, 2025 | msn.comAre Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock?March 4, 2025 | msn.comAurinia: My 2024 Sell Call Was Wrong - So I'm Upgrading To 'Hold' In 2025January 16, 2025 | seekingalpha.comAurinia Pharma Surges Pre-Market After Director Kevin Tang Discloses $10M Stock Buy: Retail Confidence SpikesDecember 11, 2024 | msn.comAurinia Pharmaceuticals: Strong Q3 Performance and Promising Outlook Justify Buy RatingNovember 9, 2024 | markets.businessinsider.comAurinia Pharmaceuticals Reports Strong Growth and Strategic RestructuringNovember 9, 2024 | markets.businessinsider.comAurinia slashes workforce by 45% to focus on lupus and autoimmune assetsNovember 9, 2024 | msn.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comAurinia Pharmaceuticals: Strong Growth Prospects Bolstered by Lupkynis Sales and Promising PipelineNovember 7, 2024 | markets.businessinsider.comAurinia Pharmaceuticals reports Q3 EPS 10c, consensus 1cNovember 7, 2024 | markets.businessinsider.comAurinia Pharmaceuticals Reports Strong Q3 Growth and RestructuringNovember 7, 2024 | markets.businessinsider.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock, Guidance And ForecastOctober 18, 2024 | benzinga.comBuy Rating Affirmed for Aurinia Pharmaceuticals on AUR200’s Clinical and Financial PromiseSeptember 7, 2024 | markets.businessinsider.comAurinia doses first subject in Phase Ia trial of AUR200 for autoimmune diseasesSeptember 6, 2024 | msn.comAurinia Pharmaceuticals Share Price (AUPH.US)August 28, 2024 | lse.co.ukAnalysts Have Conflicting Sentiments on These Healthcare Companies: uniQure (QURE), Aurinia Pharmaceuticals (AUPH) and Vertex Pharmaceuticals (VRTX)August 2, 2024 | markets.businessinsider.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call TranscriptMay 3, 2024 | msn.comAurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)May 3, 2024 | seekingalpha.comAUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Aurinia Pharmaceuticals (AUPH) and 908 Devices (MASS)May 2, 2024 | markets.businessinsider.comAurinia: Q1 Earnings SnapshotMay 2, 2024 | washingtonpost.comAurinia Pharmaceuticals Inc.February 29, 2024 | barrons.comAurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock BuybackFebruary 15, 2024 | msn.comExclusive-Kidney drug developer Aurinia fails to clinch a sale, sources sayFebruary 15, 2024 | msn.comAurinia Pharma GAAP EPS of -$0.19 misses by $0.03, revenue of $45.1M misses by $0.06MFebruary 15, 2024 | msn.comAurinia drops after Q4 miss; strategic review failsFebruary 15, 2024 | msn.comAurinia to stop development of immunotherapies after strategic reviewFebruary 15, 2024 | reuters.comExclusive: Kidney drug developer Aurinia fails to clinch a sale, sources sayFebruary 15, 2024 | reuters.comAurinia Pharma Q4 2023 Earnings PreviewFebruary 14, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Arrowhead Pharmaceuticals (ARWR)February 8, 2024 | markets.businessinsider.comAurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseFebruary 8, 2024 | msn.comAurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in JapanNovember 13, 2023 | benzinga.comAurinia Says Its Partner Otsuka Filed NDA For Voclosporin In JapanNovember 13, 2023 | markets.businessinsider.comStrong 3Q Performance and Growing Lupkynis Sales Bolster Aurinia Pharmaceuticals’ Buy Rating: An In-depth Analysis by David Martin, PhDNovember 6, 2023 | markets.businessinsider.comAurinia Pharmaceuticals Inc. (AUPH) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | seekingalpha.comAurinia Pharmaceuticals: Reassessing As It Gains TractionSeptember 27, 2023 | msn.comAurinia Pharmaceuticals Inc. (AUPH) Q2 2023 Earnings Call TranscriptAugust 3, 2023 | seekingalpha.comAurinia Pharmaceuticals Stock Returns To A Rising Relative StrengthJuly 18, 2023 | msn.comAurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueJune 29, 2023 | benzinga.comAurinia Pharmaceuticals: Still In The Game With Lupkynis SalesJune 16, 2023 | msn.comAurinia Pharmaceuticals Earnings Perspective: Return On Capital EmployedMay 18, 2023 | msn.comMKT Capital Thanks Fellow Shareholders for Their Strong Support at Aurinia's 2023 Annual MeetingMay 17, 2023 | technews.tmcnet.comNews Flash: Analysts Just Made A Sizeable Upgrade To Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ForecastsMay 9, 2023 | finance.yahoo.comBloom Burton Remains a Buy on Aurinia Pharmaceuticals (AUPH)May 6, 2023 | markets.businessinsider.comMKT Capital Issues Statement Regarding Aurinia's Disappointing First Quarter 2023 Financial ResultsMay 5, 2023 | technews.tmcnet.comAurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational ResultsMay 4, 2023 | finance.yahoo.comAurinia Pharma gains after Q1 beat and guidance raiseMay 4, 2023 | msn.com Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AUP Media Mentions By Week AUP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AUP News Sentiment▼0.000.93▲Average Computer and Technology News Sentiment AUP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AUP Articles This Week▼00▲AUP Articles Average Week Get the Latest News and Ratings for AUP and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aurinia Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Premium Brands News Bausch Health Companies News Tilray Brands News Cronos Group News Solaris Resources News Aimia News International Tower Hill Mines News Fennec Pharmaceuticals News Andean Precious Metals News Cardiol Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:AUP) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access